Elektrofi
Elektrofi is a biotechnology company developing Hypercon™, a platform that enables stable, syringe-injectable biologics at very high concentrations; and Elektroject™, a process producing protein microparticles suitable for small-volume subcutaneous delivery.
Elektrofi is a biotechnology company developing ultra-high concentration protein formulation technologies. Its Hypercon™ platform enables stable, syringe-injectable biologics at concentrations far beyond conventional limits; and its Elektroject™ process produces protein microparticles that make these formulations practical for small-volume subcutaneous delivery.
In October 2025, Halozyme announced that it was acquiring Elektrofi.
